52 results about "Hyperactive bladder" patented technology

There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).

The present invention provides improved methods for positioning of an implantable lead in a patient with an integrated EMG and stimulation clinician programmer. The integrated clinician programmer is coupled to the implantable lead, wherein the implantable lead comprises at least four electrodes, and to at least one EMG sensing electrode minimally invasively positioned on a skin surface or within the patient. The method comprises delivering a test stimulation at a stimulation amplitude level from the integrated clinician programmer to a nerve tissue of the patient with a principal electrode of the implantable lead. Test stimulations are delivered at a same stimulation amplitude level for a same period of time sequentially to each of the four electrodes of the implantable lead. A stimulation-induced EMG motor response is recorded with the integrated clinician programmer for each test stimulation on each electrode of the implantable lead via the at least one pair of EMG sensing electrodes so as to facilitate initial positioning of the implantable lead at a target stimulation region.

This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysftunction.

It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by the administration of a remedy for urinary disturbance and a preventive or remedy for hyperactive bladder not accompanied by dry mouth; and a method of screening a substance preventing/treating urinary disturbance without inhibiting the urine collection function characterized by comprising measuring and comparing the acetylcholine esterase inhibitory activity and the butyrylcholine esterase inhibitory activity of a test compound.

In some embodiments, systems and methods can include a wearable device with an electrically conductive skin interface that excites the underlying nerves from a transcutaneous surface stimulator. The device may be sized for a range of user sizes with stimulation electrodes positioned to target the appropriate nerves, such as the saphenous and/or tibial nerves. The stimulation could include burst stimulation, and involve receiving an input relating to autonomic nervous system activity of the patient, and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a solifenacin succinate-containing orally disintegrating tablet and a preparation method thereof. The orally disintegrating tablet is clinically used for treating symptoms such as frequent micturition, urgent urination and urinary incontinence caused by the overactive bladder.

A vapor delivery system and method is provided that is adapted for ablating bladder tissue to treat overactive bladder (OAB). The vapor delivery system includes an anchor tip configured anchor the system in the bladder while condensable vapor is delivered to target tissue. In one method, the vapor delivery system is advanced transurethrally into the patient to access the target tissue of the bladder, which can include a surface sensor of the bladder responsible for creating an urge incontinence sensation. The vapor delivery system includes a vapor source that provides a high quality vapor for delivery to tissue.

The present invention is related to a treatment probe and method for treating overactive bladders. The treatment probe may include a curved, rounded treatment tip designed to accommodate vaginal and urethral anatomy, an electrode assembly coupled to the treatment tip, wherein the electrode coupled to the treatment tip is configured to transfer radiofrequency energy to specific vaginal and urethral structures, a temperature measuring feature coupled to the electrode assembly, wherein the temperature measuring feature coupled to the electrode assembly is configured to monitor and regulate electrode and skin temperature, a radiofrequency handle configured to connect to the treatment tip, a connector configured to connect the radiofrequency handle to a radiofrequency generator, and a protective apparatus configured to protect the radiofrequency handle.

Disclosed is an anti-blockage urinary catheter, comprising a catheter body (1) and a balloon (2), wherein the balloon is provided on the catheter body at a site close to the tail end and the balloon is provided with a filter net (3) outside, wherein the filter net coats the tail end of the catheter body and is ovoid when in the open state. After placing the urinary catheter into the bladder, air is inflated into the balloon or water is injected into the balloon, in order to fully open the balloon and stretch the filter net to contact with the liquid in the bladder in the maximum area, thus preventing the bladder from bleeding to form blood clots, bladder stones and bladder mucosa to block the pipe orifice thus leading to overactive bladder filling.

The invention discloses a traditional Chinese medicine for treating overactive bladder after prostate electrocision. The traditional Chinese medicine is prepared from the following raw materials: pseudo-ginseng, Japanese beautyberry, red peony root, wedelia chinensis, pearl grass, sclerospora graminicola, polyporus umbellatus, oenanthe rivularis, radix cyathulae, carapax trionycis and oyster. The traditional Chinese medicine provided by the invention is free of side effects, has good patient-based compliance and is a special medicine for replacing an M cholinoceptor blocker to treat overactive bladder after prostate electrocision.

Carbamate of general formula (I), wherein R1, R2 and R3 are H, OH, NO2, SH, CN, F, Cl, Br, I, COOH, CONH2, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted with one or several F, and (C1-C4)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C5-C10)-alkyl, a substituted (C1-C10)-alkyl; and X<-> is a physiologically acceptable anion. Carbamate (I) is selective M3 receptor antagonists versus M2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particulary, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions.

The invention discloses a method for preparing 4-(2-methyl-1H-imidazole-1-yl)-2,2-diphenyl butyrylamide (1). The target product of the method is a new drug imidafenacin for treating overactive bladder. The invention provides a new synthetic route and a new preparation method; and the new method is simple and convenient to operate, mild in reaction conditions, easy to control, high in yield, good in product purity, free of pollution on the environment and suitable for industrial mass production.

The invention discloses a method to synthesize darifenacin intermediate compound with formula (I). Darifenacin is an effective for muscarine M3 receptor antagonist and can be used to cure overactive bladder diseases such as uroclepsia, urgency of urination and frequent micturition. The method takes 2,3-dihydrobenzofuran as material to produce 5-bromine-2,3-dihydrobenzofuran through bromination and then to prepare 2,3-dihydrobenzofuran-5-ethanol through grignard reaction and the introduction of ethylene oxide; finally the target compound (I) is obtained through halogenation. The method is novel in process route, with short process, simple operation, high yield, low cost and little waste(liquid, gas and solid); therefore the method is of great practical value and social economic value.

Drug delivery devices and methods of administering drugs to patients are provided. A device (50) includes a reservoir (60) containing a drug (58). The reservoir (60) is defined by a wall (64) having awater-permeable portion, such that the water-permeable portion permits water to enter the device (50) and contact the drug (58). A restraining plug (56) closes off an opening of the device (50) suchthat transient microchannels (62) form between an elastic portion (54) of the device (50) and the restraining plug (56), upon the generation of a sufficient pressure within the reservoir (60), to release the drug (58) from the device (50). Methods of treating patients for neurogenic detrusor overactivity resulting from a spinal cord injury and/or for idiopathic overactive bladder and urinary incontinence are also described.